You are here

Home

Clinical Trials: Central Nervous System Diseases

Each Clinical Trial will open in a new browser window or tab.

Return to Clinical Trials Page

Posted: Tuesday, June 28, 2022 - 12:00
Precise Transplantation of hAESCs Into the Ventricle for Parkinson's Disease.
Condition:   Parkinson's Disease
Interventions:   Biological: hAESCs treatment;   Biological: placebo (saline)
Sponsors:   Shanghai East Hospital;   Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Not yet recruiting
Posted: Thursday, April 7, 2022 - 12:00
The Safety and The Efficacy Evaluation of ET-STEM in Patients With Frontotemporal Dementia
Condition:   Frontotemporal Dementia
Intervention:   Drug: ET-STEM
Sponsor:   Samsung Medical Center
Not yet recruiting
Posted: Friday, April 1, 2022 - 12:00
CNS10-NPC-GDNF Delivered to the Motor Cortex for ALS
Condition:   Amyotrophic Lateral Sclerosis
Intervention:   Biological: CNS10-NPC-GDNF
Sponsors:   Cedars-Sinai Medical Center;   California Institute for Regenerative Medicine (CIRM)
Recruiting
Posted: Thursday, March 31, 2022 - 12:00
GV1001 Subcutaneous for the Treatment of Moderate to Severe Alzheimer's Disease(AD)
Condition:   Moderate to Severe Alzheimer's Disease
Interventions:   Drug: GV1001 Placebo;   Drug: GV1001 0.56mg;   Drug: GV1001 1.12mg
Sponsor:   GemVax & Kael
Not yet recruiting
Posted: Wednesday, March 23, 2022 - 12:00
Stem Cell Infusion in the Treatment of Patients With Neurological Complications After Ischemic Stroke
Condition:   Ischemic Stroke
Interventions:   Biological: UC-MSC infusion via intravenous route;   Biological: UC-MSC infusion via intrathecal route;   Other: standard stroke treatment and rehabilitation therapy
Sponsor:   Vinmec Research Institute of Stem Cell and Gene Technology
Recruiting
Posted: Wednesday, January 12, 2022 - 12:00
GV1001 Subcutaneous(SC) for the Treatment of Mild to Moderate Alzheimer's Disease (AD)
Condition:   Mild to Moderate Alzheimer's Disease
Interventions:   Drug: GV1001 Placebo;   Drug: GV1001 0.56mg;   Drug: GV1001 1.12mg
Sponsor:   GemVax & Kael
Not yet recruiting
Posted: Wednesday, December 22, 2021 - 12:00
Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy
Condition:   Multiple System Atrophy
Interventions:   Biological: Autologous Mesenchymal Stem Cells;   Other: Placebo
Sponsor:   Mayo Clinic
Recruiting
Posted: Wednesday, December 15, 2021 - 12:00
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Tourette Syndrome
Condition:   Tourette Syndrome
Intervention:   Biological: AlloRx
Sponsor:   The Foundation for Orthopaedics and Regenerative Medicine
Recruiting
Posted: Wednesday, December 15, 2021 - 12:00
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Stroke
Condition:   Stroke
Intervention:   Biological: AlloRx
Sponsor:   The Foundation for Orthopaedics and Regenerative Medicine
Recruiting
Posted: Thursday, December 9, 2021 - 12:00
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Parkinson's Disease
Condition:   Parkinson Disease
Intervention:   Biological: AlloRx
Sponsor:   The Foundation for Orthopaedics and Regenerative Medicine
Recruiting

Pages